A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

This trial tests a combination of zanubrutinib (a BTK inhibitor pill) with bendamustine and rituximab (standard chemotherapy and immunotherapy) for patients newly diagnosed with mantle cell lymphoma (a type of B-cell blood cancer) who are elderly (65+), unable to tolerate intensive chemotherapy, or who have a specific high-risk genetic change called TP53 alteration. **You may be eligible if...** - You are 18 or older and newly diagnosed with mantle cell lymphoma (confirmed by biopsy) - You are 65 years or older, OR you are younger than 65 but chemotherapy-intolerant, OR you have a TP53 gene change in your cancer - Your heart and kidney function are adequate **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have active hepatitis B or C - You have an immune deficiency condition - You have had significant heart failure within the past 6 months - You have another active cancer - You have a serious infection Talk to your doctor to see if this trial is right for you.